Kimialys
Claude Nogues is a CSO at Kimialys since December 2020. They have a vast experience in various roles including Team Leader at LBPA, Scientific Researcher at CNRS, and Researcher at École normale supérieure Paris-Saclay. Claude has a background in Surfaces and Interfaces, completing a Doctor of Philosophy degree at Laboratory of Molecular Materials (LMM). Their dedication to research and leadership roles in different organizations showcase their expertise in the field.
This person is not in any teams
Kimialys
We are a team of chemists and biosensor engineers gathered around a common mission: shaping the future of biodetection for a better world. Kimialys is the result of 10 years of meticulous academic research in surface chemistry. Controlling what is happening on the surface is a fundamental aspect of biosensing techniques such as rapid tests, point-of-care diagnostics, and real-time sensors. Without the right surface interactions, even the most advanced biosensors can falter, leading to misleading results. Our research efforts have always been to optimize these crucial parameters, ensuring both precision and reliable biodetection. Founded in 2020, Kimialys is leading the charge in harnessing surface chemistry to revolutionize diagnostics and drug development, all supported by our patented K-One® technology. Building on this foundation, our coated gold nanoparticles elevate rapid diagnostic tests in terms of sensitivity, specificity and reproducibility. Additionally, our expertise in sensor chip functionalisation combined with our expertise in Surface Plasmon Resonance analysis empowers us to detect, screen, and select the most suitable biologics for both diagnostic and therapeutic applications. Reliability, robustness, and adaptability are not just benefits of our technology; they are the cornerstones of the relationships we build. For every customer we collaborate with, thousands of patients stand to benefit from our work.